Most patients with ovarian cancer are diagnosed in advanced stages because of the lack of specific symptoms and the absence of effective early diagnostic methods, which leads to a poor prognosis.[2–4] In recent years, common serum biomarkers that have been used to monitor ovarian cancer progression and prognosis have included CA125 and HE4, which are also commonly used to detect ovarian cancer recurrence after surgery or chemotherapy.[5,6] However, these biomarkers lack both specificity and sensitivity in predicting cancer prognosis. This evidence concerns the gene WFDC2 and ovarian carcinoma.